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Background: No previous study has addressed the efficacy of NF-κB blockade when bladder tumors develop
acquired resistance toward CDDP-treatments. We investigated the changes in NF-κB activation and therapeutic
impact of NF-κB blockade by the novel NF-κB inhibitor dehydroxymethyl derivative of epoxyquinomicin (DHMEQ)
in CDDP-resistant bladder cancer cells.
Methods: Two human invasive bladder cancer cell lines, T24 and T24PR, were used. The T24PR cell line was newly
established as an acquired platinum-resistant subline by culturing in CDDP-containing medium for 6 months.
Expression of intranuclear p65 protein in the fractionated two cell lines was determined by Western blotting analysis.
DNA-binding activity of NF-κB was detected by electrophoretic mobility shift assay. The cytotoxic effects and induction
of apoptosis were analyzed in vivo and in vitro.
Results: Intranuclear expression and DNA-binding activity of p65 were strongly enhanced in T24PR cells compared with
those of T24 cells, and both were significantly suppressed by DHMEQ. Lowered cell viability and strong induction of
apoptosis were observed by treatment with DHMEQ alone in these chemo-resistant cells compared with parent cells.
As T24PR cells did not show dramatic cross-resistance to paclitaxel in the in vitro study, we next examined whether the
combination of DHMEQ with paclitaxel could enhance the therapeutic effect of the paclitaxel treatment in T24PR
tumors. Using mouse xenograft models, the mean volume of tumors treated with the combination of DHMEQ
(2 mg/kg) and paclitaxel (10 mg/kg) was significantly smaller than those treated with paclitaxel alone (p < 0.05),
and the reduction of tumor volume in mice treated with DHMEQ in combination with paclitaxel and paclitaxel alone as
compared to vehicle control was 66.9% and 17.0%, respectively.
Conclusion: There was a distinct change in the activation level of NF-κB between T24 and T24PR cells, suggesting
strong nuclear localization of NF-κB could be a promising target after developing acquired platinum-resistance in
bladder cancer.
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Bladder cancer is one of the most aggressive epithelial
tumors and is characterized by a high rate of early sys-
temic dissemination. Patients with metastatic bladder
cancer are routinely treated with cisplatin (CDDP)-based
systemic chemotherapy, such as M-VAC (methotrexate,
vinblastine, doxorubicin, CDDP) or GC (gemcitabine,
CDDP) regimens. Such CDDP-based regimens have gen-
erally produced a complete or partial response in ap-
proximately 50-70% of patients [1,2]. However, tumors
treated with CDDP finally acquire platinum resistance,
and no standard of care exists when tumors develop
after CDDP-treatments. These disappointing results have
prompted an ongoing search for novel agents and multi-
drug combinations in this area.
NF-κB, a heterodimer consisting mainly of p65 and
p50 proteins, functions as a transcription factor that in-
duces inflammatory cytokines and antiapoptotic pro-
teins. A growing body of evidence indicates that the
activation of NF-κB is associated with resistance to
apoptosis, expression of angiogenic proteins, and car-
cinogenesis due to its fundamental effects on cellular de-
differentiation and proliferation in malignancies [3,4].
DHMEQ, is a novel and potent NF-κB inhibitor [5] that
binds to a Cys residue of p65 and acts at the level of nu-
clear translocation [6]. The mechanism by which
DHMEQ inhibits activation of NF-κB is unique because
DHMEQ inhibits NF-κB translocation from the cyto-
plasm to the nucleus [7]. Using this agent, we previously
showed that inhibition of the NF-κB pathway led to a
potent induction of apoptosis in renal cell cancer, blad-
der cancer, and prostate cancer cells [8-10], suggesting
that the regulation of NF-κB may be a potent thera-
peutic target for urogenital cancer.
The aim of the present study was to investigate the ef-
ficacy of NF-κB blockade as a new modality for treating
platinum-resistant advanced bladder cancers. Also, we
evaluated the efficacy of other chemotherapeutic agents
such as gemcitabine, paclitaxel and carboplatin as sec-
ond line chemotherapy for CDDP-resistant bladder
tumor cell lines. To the best of our knowledge, no study
has ever addressed the impact of NF-κB blockade when
bladder tumors develop acquired resistance toward
CDDP-based treatments. Also, few studies have de-
scribed the changes in NF-κB expression in such tumors.
We believe that these results may highlight the import-
ance of NF-κB regulation as well as the clinical potency
of DHMEQ in the treatment of metastatic bladder
cancer.
Methods
Cell lines and agents
Two human invasive bladder cancer cell lines, T24 and
T24PR, were used. T24 cells were obtained from theAmerican Type Culture Collection (Rockville, MD,
USA). T24PR cells were established in our laboratory
as an acquired platinum resistant cell line [11]. Briefly,
T24 cells were grown and passaged upon reaching
confluence in medium containing CDDP over a
6-month period to develop platinum resistance. All cells
were routinely maintained in RPMI-1640 (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (Dainippon Pharmaceutical, Tokyo, Japan), at 37°C
in a humidified 5% CO2 atmosphere. DHMEQ, synthe-
sized as described previously [10,12], was dissolved in di-
methyl sulfoxide (DMSO) at a concentration of 10 mg/ml
and stored at −20°C. This stock solution was diluted in
culture medium to a final concentration of <0.1%. CDDP
and paclitaxel were kindly supplied by Nippon Kayaku Co.
(Tokyo, Japan). Gemcitabine and carboplatin were ob-
tained from Wako Pure Chemical Industries (Osaka,
Japan).
Cell extracts and western blotting analysis
Proteins were extracted from the cytoplasm and nucleus
separately using NE-PER nuclear and cytoplasmic ex-
traction reagents (Pierce Biotechnology, Rockford, IL,
USA) according to the manufacturer’s protocol. The ex-
tracted nucleus protein (20 μg) and cytoplasmic protein
(20 μg) with sample buffer containing 2-mercaptoethanol
was separated on 12.5% SDS-PAGE and transferred to a
nitrocellulose membrane (Bio-Rad Laboratories, Hercules,
CA, USA) and then incubated with 5% skim milk over-
night. The membrane was then incubated overnight with
primary antibodies against NF-κB p65 (Cell Signaling
Technology, Beverly, MA, USA), Lamin A⁄C (Santa Cruz
Biotechnology, Dallas, TX, USA), beta-actin (Sigma-
Aldrich, St. Louis, MO, USA), Bcl-2 (Santa Cruz Bio-
technology, Dallas, TX, USA) and survivin (Santa Cruz
Biotechnology, Dallas, TX, USA). After incubation with
appropriate secondary antibodies, signals were visualized
using an ECL Western blotting system (Amersham,
Piscataway, NJ, USA).
Electrophoretic mobility shift analysis
A nuclear extraction kit (Affymetrix, Santa Clara, CA,
USA) was used to prepare nuclear extracts and an
EMSA “Gel Shift” kit (Affymetrix, Santa Clara, CA,
USA) was used in gel shift assay. The binding reaction
mixture contained 2 μL of nuclear extract (at a concen-
tration of 2 μg/μL), 1 μL of poly (dI–dC), and biotin-
labeled p65 probe in binding buffer (75 mM NaCl,
1.5 mM EDTA, 1.5 mM DTT, 7.5% glycerol, 1.5% NP-
40, 15 mM Tris–HCl; pH 7.0). Samples were incubated
for 30 min at 15°C in this mixture. DNA/protein com-
plexes were separated from free DNA on a 6% non-
denaturing polyacrylamide gel in 0.25 mM TBE buffer.
The gel was transferred to a nylon membrane and
Figure 1 Cytotoxic effects of DHMEQ in T24 and T24PR cells. Cells
were incubated for 48 hours with various concentrations of DHMEQ.
Cell viability was measured by WST-1 assay. Each value represents
the mean of at least 3 individual experiments; bars ± SE. *, **p < 0.05
as compared to T24 control and T24PR control, respectively.
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substrate. The following sequence was used as a p65
probe (Affymetrix, Santa Clara, CA, USA): 5′-CATCGG
AAATTTCCGGAAATTTCCGGAAATTTCCGGC-3′.
Cell growth assay
All cell lines were seeded at a density of 5 × 103 cells per
well into 96-well culture plates. Following 24 hour incu-
bation in RPMI 1640 medium with 10% fetal bovine
serum, the cells were incubated for 48 hours with vari-
ous concentrations of DHMEQ. To evaluate the changes
of sensitivity to anticancer agents, the cells were incu-
bated for 48 hours with various concentrations of anti-
cancer agents (cisplatin, gemcitabine, paclitaxel and
carboplatin) in each cell line. In combination analysis,
cells were incubated for 48 hours with 3 μg/ml of
DHMEQ and various concentrations of chemotherapeu-
tic agents in a similar way. Cells treated with the same
concentration of DMSO were served as controls. At the
end of the incubation period, cell viability was deter-
mined using a Premix WST-1 Cell Proliferation Assay
System (Takara Bio Inc, Shiga, Japan) and microplate
spectrophotometer (Bio-Rad Laboratories, Inc, Tokyo,
Japan). The absorbance value of each well was deter-
mined at 450 nm with a 655 nm reference beam in a mi-
croplate reader (Bio-Rad, Tokyo, Japan).
Resistance factor (RF) analysis also provided a qualita-
tive measure of the extent of acquired resistance against
anticancer agents, and was calculated as the half max-
imal (50%) inhibitory concentration (IC50) of resistant
line/IC50 of parent line. IC50 values were determined in
three independent experiments. Combination index (CI)
analysis provided a qualitative measure of the extent of
drug interaction. A CI of less than 1, equal to 1 and
more than 1 indicates synergy, additive and antagonism,
respectively [13,14].
Apoptosis assay
Flow cytometric analysis was performed using transferase-
mediated nick-end labelling (TUNEL) assay to detect
apoptosis. TUNEL assay was performed using ApopTag
kits (Sigma Chemical, Atlanta, GA, USA). The cells
(1×106 cells) were seeded in 100 mm dishes and incubated
for 24 hours in RPMI 1640 medium with 10% fetal bovine
serum. Following 48 hour incubation in medium contain-
ing 10 μg/ml of DHMEQ, apoptosis was detected by flow
cytometry, and subsequent analysis was carried out ac-
cording to the manufacturer’s protocol.
Murine xenograft bladder cancer model
All animal procedures were carried out in accordance
with ARRIVE guidelines. The protocol was approved by
the Committee on the Ethics of Animal Experiments of
the Keio University {Permit Number: 10228-(1)}. Six-week-old athymic nude mice (BALB/c) with an average
body weight of 20 g were obtained from Sankyo Lab Ser-
vice Co. (Tokyo, Japan). T24PR cells (2 × 106 cells), sus-
pended in 100 μl of matrigel (Becton Dickinson
Labware, Lincoln Park, NJ, USA), were implanted sub-
cutaneously into the flank of each mouse. In the first set
of in vivo experiments, the mice were randomly assigned
to 2 groups, each consisting of 10 animals. On day 7
after cancer cell implantation, the mice were injected in-
traperitoneally with 2 mg/kg DHMEQ daily. The control
group was administered vehicle DMSO solution.
In the second set of in vivo experiments, the mice
were assigned to 3 groups (control, paclitaxel alone, or
combined paclitaxel and DHMEQ), each consisting of
10 animals. Paclitaxel (10 mg/kg) was administered intra-
peritoneally on day 14 and day 21 after cancer cell im-
plantation, while DHMEQ was injected intraperitoneally
at 2 mg/kg from day 7 after cancer cell implantation. The
mice were carefully monitored and tumor size was mea-
sured every three days. Tumor volume (V) was calculated
according to the formula V = length × width × height ×
0.52. Four weeks after implantation, the mice were sacri-
ficed and the tumors were evaluated histologically.
Immunostaining for Ki-67 and apoptosis
Formalin-fixed, paraffin-embedded tissue sections (4 μm)
were stained with hematoxylin and eosin (H&E) for tumor
pathology. These sections were deparaffinized, rehydrated,
and washed in phosphate-buffered saline. Endogenous
peroxidase was quenched. A blocking step was included
using 1% bovine serum albumin together with avidin
and biotin blocking solutions. To determine the prolif-
erative activity, Ki-67 immunostaining was performed
using an anti-Ki-67 monoclonal antibody (MIB-1;
Dako, Carpinteria, CA, USA). Apoptosis was measured
Figure 3 Basal NF-κB DNA binding activity in T24 and T24PR cells.
Proteins were separately extracted from the cytoplasm and nucleus
of T24 and T24PR cells. 2 μl nuclear extract (at a concentration of
2 μg/μl) mixed with biotin-labeled NF-κB probe for EMSA assay
was used.
Figure 2 Induction of apoptosis by DHMEQ in T24 and T24 PR cells. Cells were exposed to 10 μg/ml of DHMEQ for 48 hours. TUNEL assay
was performed and apoptosis was detected by flow cytometry. The upper left quadrant of each panel shows the populations of
apoptotic cells.
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tosis in situ detection kit (Wako Pure Chemical, Osaka,
Japan). Visualization of the immunoreaction was per-
formed with 0.06% 3,3′-diaminobenzidine (DAB) (Sigma
Chemical, Atlanta, GA, USA). A dark accumulation of
DAB in the nuclei was judged to indicate a positive reac-
tion for TUNEL and Ki-67. The apoptotic index was cal-
culated as the average number of TUNEL-positive cells in
10 areas at high power field (×400). The proliferation
index was calculated as the average number of cancer cells
with nuclei stained for Ki-67 in 10 areas at high power
field (×400).
Statistical analysis
All data are presented as the mean ± SE. Comparisons of
two different groups were performed using the Mann–
Whitney U-test. P-values <0.05 were accepted as being
statistically significant.
Statistical analyses were performed with R Statistical
Language version 2.9 and SPSS version 18.0 statistical
software package.
Results
Efficacy of NF-κB inhibition for cell survival by DHMEQ in
acquired platinum-resistant bladder cancer cells
To determine the efficacy of NF-κB inhibition by DHMEQ
for cell viability, we first conducted the viability assay of
T24 and T24PR cells in vitro. After 48 hours of incubation,
Figure 4 Nuclear and cytoplasm p65 protein expression in T24 and T24PR cells. The extracted nucleus and cytoplasmic protein (20 μg) were
immunoblotted with p65 antibody. Lamin A/C was used as a loading control for nuclear extraction, and β-actin was used as a loading control for
cytoplasm extraction.
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ner in both T24 and T24PR cells (Figure 1). However, the
IC50 of DHMEQ of T24PR cells (6.9 μg/ml) was signifi-
cantly lower than that of the parent cells (17.3 μg/ml).
Using the TUNEL assay, we also investigated apoptosis in-
duced by DHMEQ (Figure 2). The apoptotic index induced
by DHMEQ (10 μg/ml) at 48 hours was 23.6 ± 4.8% in T24
cells and 46.1 ± 8.5% (P < 0.05) in T24PR cells.
Enhancement of NF-κB activity in platinum-resistant
bladder cancer, and DHMEQ inhibits its activation
To evaluate the changes in NF-κB expression after de-
velopment of acquired platinum-resistance, we investi-
gated the status of DNA-binding activity of p65 in T24
and T24PR cells using EMSA (Figure 3). T24PR cells ex-
hibited strong nuclear activation of p65, whereas T24
cells exhibited weak activation. We also examined p65
protein expression in T24 and T24PR cells usingFigure 5 Time-dependent inhibition of NF-κB activity by DHMEQ. T24PR ce
times and then the nuclear extract was assayed by EMSA.Western blotting (Figure 4) and found that the nuclear
p65 protein expression was apparently strong in T24PR
cells as compared to T24 cells and cytoplasmic p65
levels were not different between these two cell lines.
Moreover, as shown in Figure 5, the DNA-binding activ-
ity of p65 was significantly suppressed in a time-
dependent manner after 2–6 hours of exposure to
10 μg/ml of DHMEQ in T24PR cells.
We also examined nuclear protein expression Bcl-2,
survivin and p65 in T24PR cells using Western blotting
(Figure 6). We observed dose-dependent suppression of
nuclear protein expression in Bcl-2, survivin and p65 by
DHMEQ.
Combination with DHMEQ and anticancer agents in
platinum-resistant bladder cancer cells
We next examined the sensitivity of T24 and T24PR
cells to anticancer agents including CDDP, gemcitabine,lls were incubated with or without 10 μg/ml of DHMEQ for various
Figure 6 Western blotting analysis of Bcl-2, survivin and p65 in
DHMEQ-treated cells. The extracted nucleus protein (20 μg) was
immunoblotted with p65, Bcl-2 and survivin antibodies. Lamin A/C
was used as a loading control for nuclear extraction.
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mental conditions, T24PR cells showed cross-resistance
to all anticancer agents, while the sensitivity of paclitaxel
did not change dramatically compared with the other
agents. In the combination therapies with DHMEQ in
T24PR cells, DHMEQ (3 μg/ml) could enhance the effi-
cacy of anticancer agents. We find slightly synergistic
interaction between DHMEQ and these agents and the
CI values ranged between 0.7 and 0.8, respectively.
Furthermore we evaluated the induced ability of apop-
tosis and DNA-binding activity of p65 when T24PR cells
were treated with 3 μg/ml DHMEQ alone and the com-
bination treatment of paclitaxel and 3 μg/ml DHMEQ
in vitro. TUNEL assay demonstrated that the apoptotic
index induced by DHMEQ (3 μg/ml), paclitaxel (10
nM), and their combination at 48 hours was 3.7 ± 0.9%,
24.8 ± 1.4% and 35.4 ± 6.1%, respectively (Figure 7).
EMSA assay demonstrated that no suppression of nu-




IC50 ± SE IC50 ± SE RF
cisplatin(μM) 4.5 ± 0.1 27 ± 1.5 5.9
gemcitabine(nM) 231 ± 25 910 ± 33 3.9
paclitaxel(nM) 49 ± 1.8 62 ± 2.6 1.3
carboplatin(μM) 65 ± 2.8 208 ± 9.8 3.2
Abbreviation: RF = resistance factor, CI = combination index.treatment alone, however, the suppression of nuclear ac-
tivation by 3 μg/ml of DHMEQ was observed, and it was
slightly weaker than that of 10 μg/ml of DHMEQ
(Figure 8).
Antitumor effects of DHMEQ with or without paclitaxel in
a murine xenograft model of platinum-resistant bladder
cancer
Next we examined the efficacy of DHMEQ in a murine
xenograft model of the platinum-resistant subline T24PR
cells. As shown in Figure 9, DHMEQ (2 mg/kg) adminis-
tered intraperitoneally significantly suppressed tumor
growth of the murine xenograft models of T24PR, show-
ing the tumor volume was decreased to 51.2% compared
to the control group on the 28th day. Significant differ-
ences in tumor volume were observed between the
DHMEQ-treated group and control group as early as the
19th day after tumor implantation (P < 0.05).
As shown in Table 1, the results of the cell viability assay
indicated that cross-resistance to paclitaxel is relatively
small in T24PR cells. We then investigated the effect of
paclitaxel on a T24PR xenograft tumor model and exam-
ined whether the combination of DHMEQ with paclitaxel
could enhance the therapeutic effect of the paclitaxel
treatment. As shown in Figure 10, paclitaxel (10 mg/kg)
was administered intraperitoneally on day 14 and day 21
after cancer cell implantation, and the mean tumor vol-
ume (403.8 ± 36.3 mm3) on day 28 of tumors treated with
paclitaxel treatment alone was significantly smaller than
those treated with vehicle control (486.3 ± 25.3 mm3) (p <
0.05). Furthermore, the mean tumor volume (160.8 ±
10.2 mm3) of tumors treated with the combination of
DHMEQ and paclitaxel was significantly smaller than
those treated with vehicle controls or those treated with
paclitaxel treatment alone (p < 0.05, each).
Proliferation and apoptotic index in T24PR tumors after
combined therapy with DHMEQ and paclitaxel
The apoptotic index of T24PR tumors was significantly
increased in the paclitaxel-treated group (3.9 ± 0.9%) and
combination group (10.0 ± 0.8%) compared to the con-
trol group (1.5 ± 0.3%, p < 0.05) (Figure 11, and Table 2),
suggesting the apoptotic index in the combination groupnts in T24 and T24PR cells
combination with DHMEQ (3 μg/ml) in T24PR
IC50 ± SE CI
9.8 ± 0.6 0.75
124 ± 5.1 0.71
20 ± 1.1 0.79
75 ± 5.5 0.74
Figure 7 Induction of apoptosis by DHMEQ 3 μg/ml, paclitaxel 10nM, or their combination treatment. Cells were exposed to DHMEQ 3 μg/ml,
paclitaxel 10nM, or their combination for 48 hours. TUNEL assay was performed and apoptosis was detected by flow cytometry. The upper left
quadrant of each panel shows the populations of apoptotic cells.
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group (p < 0.05). In addition, similar results could be ob-
tained in the analyses of the proliferation index of the
tumors, showing the proliferation index in the combin-
ation group (34.3 ± 3.6%) differed significantly from that
in the paclitaxel-treated group (69.1 ± 4.8%, p < 0.05)
(Figure 11, and Table 2).
Discussion
Bladder cancer is one of the most aggressive epithelial
tumors and is characterized by a high rate of early sys-
temic dissemination. The prognosis for patients with ad-
vanced or metastatic bladder cancer remains poor [15].
The vast majority of patients treated with CDDP-based
regimens develop progressive disease within 8 months of
treatment, and the median survival is reported to beFigure 8 NF-κB DNA binding activity in DHMEQ 3 μg/ml, paclitaxel 10nM,
from the cytoplasm and nucleus of each treated T24PR cells after the treat
nuclear extract (at a concentration of 2 μg/μl) mixed with biotin-labeled Nonly 13–15 months [2,16]. Furthermore, there is still
no approved treatment option for patients who develop
disease recurrence or progression after CDDP-based
regimens [17].
In the present study, we have demonstrated the cyto-
toxic effect of DHMEQ, a potent NF-κB inhibitor, after
the development of acquired platinum-resistant bladder
cancer cells. Strong nuclear localization of NF-κB was
observed in T24PR cells whereas relatively weak nuclear
expression of NF-κB was observed in T24 cells. DHMEQ
reversibly inhibited the DNA-binding activity of NF-κB
and consequently induced a significant dose-dependent
decrease in cell viability due to apoptosis in T24PR cells.
We further examined the efficacy of DHMEQ using
mouse xenograft tumors, and observed a significant in-
hibitory effect on tumor growth especially in DHMEQ-or their combination treatment. Proteins were separately extracted
ment of DHMEQ 3 μg/ml, paclitaxel 10nM, or their combination. 2 μl
F-κB probe for EMSA assay was used.
Figure 10 Effect of DHMEQ in combination with paclitaxel on tumor
growth in T24PR mouse xenograft model. T24PR cells (2 × 106 cells)
were implanted in the flank of athymic nude mice. Seven days after
implantation, daily intraperitoneal administration of 2 mg/kg of
DHMEQ was started. Paclitaxel (10 mg/kg) was administered
intraperitoneally on day 14 and day 21 after cancer cell implantation.
The tumor volume of each animal was monitored and compared with
that in the vehicle-treated control group or paclitaxel-treated
group. : *< 0.05, **< 0.01 compared with another group. Each value
represents the mean ± SE.
Figure 9 Effect of DHMEQ on tumor growth in T24PR mouse
xenograft model. T24PR cells (2 × 106 cells) were implanted in the
flank of athymic nude mice. Seven days after implantation, daily
intraperitoneal administration of 2 mg/kg of DHMEQ was started.
The tumor volume of each animal was monitored and compared
with that in the vehicle-treated control group. : *< 0.05, compared
with control group. Each value represents the mean ± SE.
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DHMEQ may be useful even in acquired platinum-
resistant tumors and shed light on the impact of NF-κB
inhibition as a new modality when tumors develop ac-
quired resistance toward CDDP-treatments.
The DNA-binding activity of p65 was significantly
inhibited after 2–6 hours of 10 μg/ml of DHMEQ and
then gradually recovered. DHMEQ covalently binds to
the cysteine residue to induce irreversible inhibition
[18,19]. However, after a long incubation period, possible
newly formed NF-κB appears. We think inhibition of
NF-κB for several hours would be sufficient to increase
the drug sensitivity. So we believe that DHMEQ has a
long-lived efficacy without continuing inhibition of NF-
κB translocation to the nucleus. In fact, we have exam-
ined and reported similar cytotoxic results for DHMEQ
in various types of cancer cells, even though the NF-κB
inhibition is short-lived [9,12,20]. Furthermore, we have
shown that Bcl-2 and survivin were suppressed by
DHMEQ in a dose-dependent manner. It is likely that
the increase of drug sensitivity is due to the decrease of
anti-apoptosis protein expression in our present study.
NF-κB activation has been found to be involved in
many types of cancer including genitourinary cancer
such as prostate cancer and renal cell cancer [21-23]. In
bladder tumors as well, the impact of NF-κB activation
on tumorigenesis has been described [24] and our previ-
ous work focused on the efficacy of NF-κB blockade by
DHMEQ in a mouse xenograft model of invasive bladder
cancer KU-19-19 cells [10]. Also, several researchers
attempted to examine the association between the status
of NF-κB expression and resistance to chemotherapy in
bladder tumors. Using immunohistochemical analysis
from 116 bladder cancer patients, Levidou et al. reported
a close association between the aggressiveness of bladder
tumors and nuclear NF-κB expression, and suggested
NF-κB expression has an impact as an independent indi-
cator for prognosis in bladder UC patients [24]. Wang
et al. also reported that NF-κB activity and sensitivity to
chemotherapy are inversely correlated in cancer treat-
ments [25]. Inhibition of NF-κB not only leads to en-
hanced apoptosis but also to increased sensitivity to
radiation or chemotherapy in several tumor cells such as
fibrosarcoma and colorectal cancer cell lines as well as
xenograft models or pancreatic carcinoma cells [25-27].
With regard to the association between NF-κB activa-
tion/expression and chemoresistance, Antoon et al. re-
ported that the breast cancer chemo-resistance cell line
MCF-7TN-R overexpressed NF-κB. Furthermore, inhib-
ition of the NF-κB cascade with a sphingosine kinase-2
inhibitor decreased NF-κB activation as well as tumor
growth in vitro and in vivo [26].
Paclitaxel, which is one typical taxane agent, has been
used in patients with advanced urothelial carcinoma
Figure 11 Proliferation and apoptotic index in T24PR cells treated with DHMEQ in combination with paclitaxel. Immunohistochemical study of
T24PR xenograft tumors from mice treated with DHMEQ and/or paclitaxel. (A) Hematoxylin–eosin (HE) staining, (B) TUNEL staining, and (C) Ki-67
staining (Magnification is 1:400).
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apy. Paclitaxel alone yields a 42% response rate against
urothelial carcinoma when used as a first-line treatment
[27], but yields only a 10% response rate in patients who
were treated previously [28]. Considering the low re-
sponse rate of paclitaxel when used alone as a second-line
treatment, its combinations with gemcitabine, cisplatin,
carboplatin, and ifosfamide have been investigated, and
the response rate was found to increase to 15–40%
[28-31]. In the present study, examining further the clin-
ical potency of DHMEQ, we investigated the efficacy of
combination therapy with paclitaxel and DHMEQ in
platinum-resistant tumors. Indeed, the results showed a
significant difference in tumor growth between the
DHMEQ-only group and combination-treated group. AsTable 2 Suppression of tumor growth by DHMEQ in combina
tumor volume (mm3)
control 486.3 ± 25.3
paclitaxel 403.8 ± 36.3*
palitaxel + DHMEQ 160.8 ± 20.3*, **
*P < 0.05 compared with control; **P < 0.05 compared with paclitaxel.shown in Figure 10, paclitaxel inhibited the growth of
T24PR tumors, however, its combination with DHMEQ
had a stronger antitumor effect. The reduction of tumor
volume in tumors treated with the combination treatment
and paclitaxel alone treatment as compared to vehicle
control was 66.9% and 17.0%, respectively. Therefore, we
propose that combination therapy consisting of taxane
agents and DHMEQ may be an effective choice for pa-
tients with CDDP refractory bladder tumor.
Conclusion
In summary, there was a distinct change in the expres-
sion of NF-κB between T24 and T24PR cells, suggesting
strong nuclear localization of NF-κB was observed after
the development of acquired platinum-resistance intion with paclitaxel in T24PR mouse xenograft model
apoptotic index (%) proliferation index (%)
1.5 ± 0.3 83.7 ± 3.3
3.9 ± 0.9* 69.1 ± 4.8*
10.0 ± 0.8*, ** 34.3 ± 3.6*, **
Ito et al. BMC Cancer  (2015) 15:324 Page 10 of 11bladder cancer. While NF-κB blockade leads to a signifi-
cant decrease in cell viability due to apoptosis, we be-
lieve that regulation of the NF-κB pathway may be a
potent therapeutic target in platinum-resistant bladder
cancer.
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